In line with these findings, N-MYC overexpression in multiple preclinical models drives prostate cancer that, at molecular level, resembles clinical neuroendocrine prostate cancers and sensitizes to the Aurora kinase and EZH2 inhibitors [95]. The gene discussed is MYCN; the disease is prostate cancer.